Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC plus prednisolone versus placebo plus prednisolone for first-line severe acute GVHD after allogeneic stem cell transplantation
NL-OMON29599Phase 3Completed
- Sponsor
- HOVON
- Start
- May 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Provacel and prednisolone in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by HOVON. Primary endpoint: Response at day 57 without treatment failure. Started May 2014; status: completed.
02
Drugs
Provacelprednisolone
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON29599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29599.